^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Bendamustine, rituximab + idelalisib (category 3)
Secondary therapy:
bendamustine
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation...Preferred regimens...Idelalisib + rituximab